Upadacitinib: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Upadacitinib == | {{Short description|An article about the medication Upadacitinib}} | ||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 123456789 | |||
| image = Upadacitinib.svg | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Upadacitinib | |||
}} | |||
[[ | '''Upadacitinib''' is a medication used in the treatment of several inflammatory conditions. It is classified as a [[Janus kinase inhibitor]], which works by interfering with the signaling pathways that lead to inflammation. | ||
==Mechanism of Action== | |||
Upadacitinib functions by selectively inhibiting the activity of [[Janus kinase]] (JAK) enzymes. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that are involved in hematopoiesis and immune function. By inhibiting JAKs, upadacitinib reduces the inflammatory response that is characteristic of autoimmune diseases. | |||
== Medical Uses == | ==Medical Uses== | ||
Upadacitinib is primarily | Upadacitinib is primarily used in the treatment of: | ||
* [[Rheumatoid arthritis]] | |||
* [[Psoriatic arthritis]] | |||
* [[Atopic dermatitis]] | |||
* [[Ulcerative colitis]] | |||
===Rheumatoid Arthritis=== | |||
In patients with moderate to severe [[rheumatoid arthritis]], upadacitinib is used to reduce symptoms and improve physical function. It is often prescribed when patients have had an inadequate response to one or more [[disease-modifying antirheumatic drugs]] (DMARDs). | |||
===Psoriatic Arthritis=== | |||
For individuals with active [[psoriatic arthritis]], upadacitinib helps in reducing joint pain and swelling, as well as improving skin symptoms associated with the condition. | |||
===Atopic Dermatitis=== | |||
Upadacitinib is also indicated for the treatment of moderate to severe [[atopic dermatitis]] in adults and adolescents who are candidates for systemic therapy. | |||
== | ===Ulcerative Colitis=== | ||
In the context of [[ulcerative colitis]], upadacitinib is used to induce and maintain clinical remission in patients with moderate to severe disease. | |||
== Side Effects == | ==Side Effects== | ||
Common side effects of upadacitinib include | Common side effects of upadacitinib include: | ||
* [[Upper respiratory tract infections]] | |||
* [[Nausea]] | |||
* [[Headache]] | |||
* [[Hypertension]] | |||
Serious side effects may include: | |||
* Increased risk of serious infections | |||
* [[Thrombosis]] | |||
* [[Liver enzyme elevations]] | |||
== Related | ==Administration== | ||
Upadacitinib is administered orally, typically once daily. The dosage may vary based on the specific condition being treated and the patient's response to the medication. | |||
==Related pages== | |||
* [[Janus kinase inhibitor]] | |||
* [[Rheumatoid arthritis]] | * [[Rheumatoid arthritis]] | ||
* [[Psoriatic arthritis]] | * [[Psoriatic arthritis]] | ||
* [[Atopic dermatitis]] | * [[Atopic dermatitis]] | ||
* [[ | * [[Ulcerative colitis]] | ||
[[Category:Janus kinase inhibitors]] | [[Category:Janus kinase inhibitors]] | ||
[[Category:Immunosuppressants]] | [[Category:Immunosuppressants]] | ||
[[Category:Drugs | [[Category:Drugs used in rheumatology]] | ||
<gallery> | |||
File:Upadacitinib.svg|Upadacitinib | |||
</gallery> | |||
Latest revision as of 01:51, 20 February 2025
An article about the medication Upadacitinib
| Upadacitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Upadacitinib is a medication used in the treatment of several inflammatory conditions. It is classified as a Janus kinase inhibitor, which works by interfering with the signaling pathways that lead to inflammation.
Mechanism of Action[edit]
Upadacitinib functions by selectively inhibiting the activity of Janus kinase (JAK) enzymes. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that are involved in hematopoiesis and immune function. By inhibiting JAKs, upadacitinib reduces the inflammatory response that is characteristic of autoimmune diseases.
Medical Uses[edit]
Upadacitinib is primarily used in the treatment of:
Rheumatoid Arthritis[edit]
In patients with moderate to severe rheumatoid arthritis, upadacitinib is used to reduce symptoms and improve physical function. It is often prescribed when patients have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
Psoriatic Arthritis[edit]
For individuals with active psoriatic arthritis, upadacitinib helps in reducing joint pain and swelling, as well as improving skin symptoms associated with the condition.
Atopic Dermatitis[edit]
Upadacitinib is also indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents who are candidates for systemic therapy.
Ulcerative Colitis[edit]
In the context of ulcerative colitis, upadacitinib is used to induce and maintain clinical remission in patients with moderate to severe disease.
Side Effects[edit]
Common side effects of upadacitinib include:
Serious side effects may include:
- Increased risk of serious infections
- Thrombosis
- Liver enzyme elevations
Administration[edit]
Upadacitinib is administered orally, typically once daily. The dosage may vary based on the specific condition being treated and the patient's response to the medication.
Related pages[edit]
- Janus kinase inhibitor
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis
- Ulcerative colitis
-
Upadacitinib
